ARGENICA THERAPEUTICS LTD

Argenica Therapeutics (AGN.AX) faces a flat 0% 24‑hour trade at AUD 0.11, yet its europrotective peptide pipeline and global reach offer long‑term growth potential amid market volatility.

Argenica Therapeutics shares dip 20 % amid a market correction, yet new UK/Swiss lab data strengthens xaranetide’s promise as a multitarget neuroprotective stroke therapy, positioning the firm for rapid regulatory progress and investor confidence.

Argenica Therapeutics drops 20% as new neuroprotective data on xaranetide shows multi‑target, voltage‑dependent ion‑channel inhibition, boosting stroke treatment prospects.